CSL's Hemgenix Authorized by Health Canada as Gene Therapy for Hemophilia B
By Robb M. Stewart
Australia biotechnology company CSL's Hemgenix has been authorized by Health Canada as the first gene therapy for the treatment of the rare bleeding disorder hemophilia B.
Hemgenix is a one-time, single-dose treatment for adults who require routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
CSL said the approval is based on the results of an ongoing late-stage trial of 54 participants, the largest gene therapy trial in hemophilia B to date. Data from the Phase III, open label, single-dose, single-arm study found that 96% of patients following infusion of Hemgenix discontinued use of prophylaxis and remained free of previous continuous routine prophylaxis therapy, the company said.
Hemgenix was approved by the U.S. Food and Drug Administration and was granted conditional marketing authorization by the European Commission for the European Union and European Economic Area, and the U.K.'s Medicines and Healthcare products Regulatory Agency.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
October 26, 2023 14:49 ET (18:49 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks